$XBI $89.09 |
Pipeline Updates
$FNCH Finch Therapeutics Provides an Update on its Phase 3 Trial of CP101 in Recurrent C. difficile Infection. source
$AMRX Amneal Enters U.S. Biosimilars Market With Approval of RELEUKO™ (filgrastim-ayow). source
$KPTI Karyopharm Provides U.S. Regulatory Update on Selinexor in Advanced or Recurrent Endometrial Cancer. source
$TLSA On March 1, 2022, Tiziana Life Sciences LTD (the “Company”) issued a news service announcement in the United States announcing StemPrintER Demonstrates Prognostic Utility in TransATAC Cohort.. source
$JAGX Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas. source
$DRRX DURECT Corporation Doses First European Patient in Phase 2b AHFIRM Study of Larsucosterol(DUR-928) in Severe Alcohol-Associated Hepatitis. source
$GILD Gilead Receives Complete Response Letter From U.S. FDA for Investigational Lenacapavir Due to Vial Compatability Issues. source
$URGN UroGen Submits Investigational New Drug Application Supporting Planned Phase 1 Clinical Study of UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer. Source
$RDUS Radius Health Files sNDA for TYMLOS® in Men with Osteoporosis. source
$TFFP TFF Pharmaceuticals and Catalent Announce New Inhalation Dry Powder Development and Manufacturing Agreement. source
$LPCN Lipocine Announces Regulatory Guidance on LPCN 1144 in Non-cirrhotic NASH. source
$CABA U.S. Food and Drug Administration Grants Cabaletta Bio Fast Track Designation for MuSK-CAART. source
$NTLA Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid Leukemia. source
$CRDL Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial. source
$ALKS Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer. source
$HCM HUTCHMED Receives Approval to Commercialize ELUNATE® in Macau. source
$LEGN CARVYKTI™ (ciltacabtagene autoleucel), BCMA-Directed CAR-T Therapy, Receives U.S. FDA Approval for the Treatment of Adult Patients With Relapsed or Refractory Multiple Myeloma. source
$AQST Aquestive Therapeutics Presented Positive Topline Phase 1 Results for AQST-109 Epinephrine Oral Film at American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting. source
$CTIC CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia. source
Posted by FS
Comments